摘要
T淋巴母细胞淋巴瘤(T-LBL)是一种罕见的具有侵袭性的非霍奇金淋巴瘤,2022年版世界卫生组织(WHO)诊断标准认为T-LBL与急性T淋巴细胞白血病(T-ALL)是同一疾病的不同阶段,骨髓中原始细胞比例<25%者为T-LBL,≥25%者为T-ALL。虽然其在临床特征和实验室特征方面均与ALL相似,但与ALL具有确定的预后因素不同,既往关于T-LBL预后因素的研究往往因不同的研究分组或较少的病例数而有所差异。近年来通过ALL样方案的应用,无预后不良因素的T-LBL患者能实现良好的治疗效果,然而对于有预后不良因素的患者应给予个性化的治疗,因此急需建立明确的预后模型,以实现对T-LBL患者的风险分层。文章从人口学特征、临床特征、遗传学、影像学、治疗等多个方面对T-LBL的预后影响因素的国内外研究进展作一综述。
T lymphoblastic lymphoma(T-LBL)is a kind of rare and aggressive non-Hodgkin lymphomas.The 2022 version of World Health Organization(WHO)considers T-LBL and T acute lymphoblastic leukemia(T-ALL)to be the different stages of the same disease;and the ratio of bone marrow original cells<25%was treated as T-LBL and the ratio of bone marrow original cells≥25%was T-ALL.Although T-LBL is similar to ALL in the clinical and laboratory features,it is different from ALL with definite prognostic factors.Previous studies on prognostic factors of T-LBL are often different due to different study groups or small number of cases.In recent years,T-LBL patients without adverse prognostic factors could achieve good therapeutic effects thanks to the application of ALL-like regimen,while patients with adverse prognostic factors should be given personalized treatment.Therefore,it is urgent to establish a clear prognostic model to achieve risk stratification for T-LBL patients.This article reviews the research progress of prognostic factors of T-LBL from the aspects of demographic characteristics,clinical characteristics,genetics,imaging and treatment.
作者
张峰茹
苏丽萍
Zhang Fengru;Su Liping(Second Hospital of Shanxi Medical University,Taiyuan 030001,China;Department of Hematology,Shanxi Province Cancer Hospital,Shanxi Hospital Affiliated to Cancer Hospital,Chinese Academy of Medical Sciences,Cancer Hospital Affiliated to Shanxi Medical University,Taiyuan 030013,China)
出处
《肿瘤研究与临床》
CAS
2024年第4期310-314,共5页
Cancer Research and Clinic
关键词
造血干细胞移植
T淋巴母细胞白血病/淋巴瘤
遗传学
分子分型
预后
Hematopoietic stem cell transplantation
T lymphoblastic leukemia/lymphoma
Genetics
Molecular typing
Prognosis
